Pharmacological aspects of neonatal antidepressant withdrawal

Obstetrical and Gynecological Survey

Volumn 63, Issue 4, 2008, Pages 267-279

  Ter Horst, Peter G J ^a   Jansman, Frank G A ^a,b   Van Lingen, Richard A ^a   Smit, Jan Pieter ^b   De Jong Van Den Berg, Lolkje T W ^b   Brouwers, Jacobus R B J ^b  

^a ISALA HOSPITAL   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; NEFAZODONE; OCTAMER TRANSCRIPTION FACTOR 4; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

APNEA; BRAIN DISEASE; BRAIN HEMORRHAGE; COGNITION; CONVULSION; CYANOSIS; DEPRESSION; DOWN REGULATION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG TRANSPORT; DYSPNEA; EEG ABNORMALITY; ERYTHEMA; FEEDING DISORDER; FETUS DISTRESS; GENETIC POLYMORPHISM; GESTATION PERIOD; HEART RATE; HUMAN; HYPERREFLEXIA; HYPOGLYCEMIA; HYPOTHERMIA; IRRITABILITY; LIPID SOLUBILITY; MUSCLE HYPERTONIA; MUSCLE HYPOTONIA; NERVOUSNESS; NEUROTRANSMISSION; NYSTAGMUS; PETECHIA; PLACENTA; PNEUMOTHORAX; PRENATAL CARE; PUERPERAL DEPRESSION; PULMONARY HYPERTENSION; RESPIRATORY DISTRESS; RESTLESSNESS; REVIEW; SEIZURE; SIDE EFFECT; SPONTANEOUS ABORTION; TERATOGENESIS; TREMOR; VOMITING; WITHDRAWAL SYNDROME;

ANTIDEPRESSIVE AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSIVE DISORDER; FEMALE; HUMANS; INFANT, NEWBORN; NEONATAL ABSTINENCE SYNDROME; POLYMORPHISM, GENETIC; PREGNANCY; PREGNANCY OUTCOME;

EID: 41149107445     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/OGX.0b013e3181676be8     Document Type: Review

References (171)

1. Andersson L, Sundstrom-Poromaa I, Wulff M, et al. Implications of antenatal depression and anxiety for obstetric outcome. Obstet Gynecol 2004;104:467-476.
2. Bennett HA, Einarson A, Taddio A, et al. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004;103:698-709.
3. Newport DJ, Wilcox MM, Stowe ZN. Antidepressants during pregnancy and lactation: defining exposure and treatment issues. Semin Perinatol 2001;25:177-190.
4. Nicholson WK, Setse R, Hill-Briggs F, et al. Depressive symptoms and health-related quality of life in early pregnancy. Obstet Gynecol 2006;107:798-806.
5. Orr ST, Miller CA. Maternal depressive symptoms and the risk of poor pregnancy outcome. Review of the literature and preliminary findings. Epidemiol Rev 1995;17:165-171.
6. Eberhard-Gran M, Eskild A, Opjordsmoen S. Treating mood disorders during pregnancy: safety considerations. Drug Saf 2005;28:695-706.
7. Headley J, Northstone K, Simmons H, et al. Medication use during pregnancy: data from the Avon Longitudinal Study of Parents and Children. Eur J Clin Pharmacol 2004;60:355-361.
8. Cohen LS, Nonacs RM, Bailey JW, et al. Relapse of depression during pregnancy following antidepressant discontinuation: a preliminary prospective study. Arch Womens Ment Health 2004;7:217-221.
9. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006 1;295:499-507.
10. Serretti A, Zanardi R, Franchini L, et al. Pharmacogenetics of selective serotonin reuptake inhibitor response: a 6-month follow-up. Pharmacogenetics 2004;14:607-613.
11. Viguera AC, Baldessarini RJ, Friedberg J. Discontinuing antidepressant treatment in major depression. Harv Rev Psychiatry 1998;5:293-306.
12. Rubinchik SM, Kablinger AS, Gardner JS. Medications for panic disorder and generalized anxiety disorder during pregnancy. Prim Care Companion J Clin Psychiatry 2005;7:100-105.
13. Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004;191:398-407.
14. Rubin JD, Ferencz C, Loffredo C. Use of prescription and non-prescription drugs in pregnancy. The Baltimore-Washington Infant Study Group. J Clin Epidemiol 1993;46:581-589.
15. Brocklebank JC, Ray WA, Federspiel CF, et al. Drug prescribing during pregnancy. A controlled study of Tennessee Medicaid recipients. Am J Obstet Gynecol 1978;132:235-244.
16. Buitendijk S, Bracken MB. Medication in early pregnancy: prevalence of use and relationship to maternal characteristics. Am J Obstet Gynecol 1991;165:33-40.
17. Olesen C, Steffensen FH, Nielsen GL, et al. Drug use in first pregnancy and lactation: a population-based survey among Danish women. The EUROMAP group. Eur J Clin Pharmacol 1999;55:139-144.
18. Splinter MY, Sagraves R, Nightengale B, et al. Prenatal use of medications by women giving birth at a university hospital. South Med J 1997;90:498-502.
19. Henry A, Crowther C. Patterns of medication use during and prior to pregnancy: the MAP study. Aust N Z J Obstet Gynaecol 2000;40:165-172.
20. Egen-Lappe V, Hasford J. Drug prescription in pregnancy: analysis of a large statutory sickness fund population. Eur J Clin Pharmacol 2004;60:659-666.
21. Teratology of paroxetine: evidence for cardiovascular malformations. 2005. Available at: http://www fda gov/medwatch/safety/2005/ paxil_dearhcp_letter.pdf.
22. Myllinen P. In Search of Models for Hepatic and Placental Pharmacokinetics. Thesis. Finland: Department of Pharmacology and Toxicology, University of Oulu, 2003.
23. Unadkat JD, Dahlin A, Vijay S. Placental drug transporters. Curr Drug Metab 2004;5:125-131.
24. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 2004;43:487-514.
25. Hakkola J, Raunio H, Purkunen R, et al. Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy. Biochem Pharmacol 1996;52:379-383.
26. Ganapathy V, Prasad PD, Ganapathy ME, et al. Placental transporters relevant to drug distribution across the maternal-fetal interface. J Pharmacol Exp Ther 2000;294:413-420.
27. Molsa M, Heikkinen T, Hakkola J, et al. Functional role of P-glycoprotein in the human blood-placental barrier. Clin Pharmacol Ther 2005;78:123-131.
28. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003;42:59-98.
29. Balayssac D, Authier N, Cayre A, et al. Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicol Lett 2005;156:319-329.
30. Varma MV, Ashokraj Y, Dey CS, et al. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 2003;48:347-359.
31. Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev 2004;36:57-104.
32. Gil S, Saura R, Forestier F, et al. P-glycoprotein expression of the human placenta during pregnancy. Placenta 2005;26:268-270.
33. Tanabe M, Ieiri I, Nagata N, et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001;297:1137-1143.
34. Smit JW, Huisman MT, van Tellingen O, et al. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest 1999;104:1441-1447.
35. Ganapathy V, Prasad PD. Role of transporters in placental transfer of drugs. Toxicol Appl Pharmacol 2005;207(suppl 2):381-387.
36. Sata R, Ohtani H, Tsujimoto M, et al. Functional analysis of organic cation transporter 3 expressed in human placenta. J Pharmacol Exp Ther 2005;315:888-895.
37. Cool DR, Liebach FH, Ganapathy V. Interaction of fluoxetine with the human placental serotonin transporter. Biochem Pharmacol 1990;40:2161-2167.
38. Kallen BA, Otterblad OP. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 2003;17:255-261.
39. Del Rio J, Montero D, De Ceballos ML. Long-lasting changes after perinatal exposure to antidepressants. Prog Brain Res 1988;73:173-187.
40. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. 5th ed. Baltimore: Williams & Wilkins, 1998.
41. Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002;159:1889-1895.
42. Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999;55:503-508.
43. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002;159:2055-2061.
44. Oberlander TF, Misri S, Fitzgerald CE, et al. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004;65:230-237.
45. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998;279:609-610.
46. McElhatton PR, Garbis HM, Elefant E, et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol 1996;10:285-294.
47. Einarson A, Fatoye B, Sarkar M, et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 2001;158:1728-1730.
48. Einarson A, Bonari L, Voyer-Lavigne S, et al. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Can J Psychiatry 2003;48:106-110.
49. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 2005;14:823-827.
50. Stanford MS, Patton JH. In utero exposure to fluoxetine HCl increases hematoma frequency at birth. Pharmacol Biochem Behav 1993;45:959-962.
51. Hemels ME, Einarson A, Koren G, et al. Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. Ann Pharmacother 2005;39:803-809.
52. Glaxo Smith Kline. Preliminary report on bupropion in pregnancy and the occurrence of cardiovascular and major congenital malformation. Data on File. Glaxo Smith Kline, UK, 2005.
53. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354:579-587.
54. Gentile S. The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf 2005;28:137-152.
55. Briggs GG. Drug effects on the fetus and breast-fed infant. Clin Obstet Gynecol 2002;45:6-21.
56. Hines RN, Adams J, Buck GM, et al. NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of fluoxetine. Birth Defects Res B Dev Reprod Toxicol 2004;71:193-280.
57. Djulus J, Koren G, Einarson TR, et al. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J Clin Psychiatry 2006;67:1280-1284.
58. Cole JA, Modell JG, Haight BR, et al. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007;16:474-484.
59. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005;44:989-1008.
60. Wisner KL, Perel JM, Wheeler SB. Tricyclic dose requirements across pregnancy. Am J Psychiatry 1993;150:1541-1542.
61. Hostetter A, Stowe ZN, Strader JR Jr, et al. Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depress Anxiety 2000;11:51-57.
62. Loebstein R, Lalkin A, Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet 1997;33:328-343.
63. Loebstein R, Koren G. Clinical relevance of therapeutic drug monitoring during pregnancy. Ther Drug Monit 2002;24:15-22.
64. Loebstein R, Koren G. Clinical pharmacology and therapeutic drug monitoring in neonates and children. Pediatr Rev 1998;19:423-428.
65. Altshuler LL, Hendrick VC. Pregnancy and psychotropic medication: changes in blood levels. J Clin Psychopharmacol 1996;16:78-80.
66. Franssen EJ, Meijs V, Ettaher F, et al. Citalopram serum and milk levels in mother and infant during lactation. Ther Drug Monit 2006;28:2-4.
67. Gow PJ, Ghabrial H, Smallwood RA, et al. Neonatal hepatic drug elimination. Pharmacol Toxicol 2001;88:3-15.
68. Lattimore KA, Donn SM, Kaciroti N, et al. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J Perinatol 2005;25:595-604.
69. http://medicine.iupui.edu/flockhart/table.htm. Accessed November 2006.
70. Wisner KL, Gelenberg AJ, Leonard H, et al. Pharmacologic treatment of depression during pregnancy. JAMA 1999;282:1264-1269.
71. Brazier JL, Ritter J, Berland M, et al. Pharmacokinetics of caffeine during and after pregnancy. Dev Pharmacol Ther 1983;6:315-322.
72. Rudorfer MV, Potter WZ. Metabolism of tricyclic antidepressants. Cell Mol Neurobiol 1999;19:373-409.
73. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005;5:6-13.
74. Tracy TS, Venkataramanan R, Glover DD, et al. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol 2005;192:633-639.
75. Wadelius M, Darj E, Frenne G, et al. Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther 1997;62:400-407.
76. Handschin C, Meyer UA. Induction of drug metabolism: the role of nuclear receptors. Pharmacol Rev 2003;55:649-673.
77. Wang H, LeCluyse EL. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin Pharmacokinet 2003;42:1331-1357.
78. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004;9:442-473.
79. Malhotra AK, Murphy GM Jr, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004;161:780-796.
80. Murphy GM Jr, Kremer C, Rodrigues HE, et al. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003;160:1830-1835.
81. Mackenzie PI, Gregory PA, Lewinsky RH, et al. Polymorphic variations in the expression of the chemical detoxifying UDP glucuronosyltransferases. Toxicol Appl Pharmacol 2005;207(suppl 2):77-83.
82. Bondy B. Pharmacogenomics in depression and antidepressants. Dialogues Clin Neurosci 2005;7:223-230.
83. Del Tredici AL, Schiffer HH, Burstein ES, et al. Pharmacology of polymorphic variants of the human 5-HT1A receptor. Biochem Pharmacol 2004;67:479-490.
84. DeVane CL, Stowe ZN, Donovan JL, et al. Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: challenges and opportunities. J Psychopharmacol 2006;20(suppl 4):54-59.
85. Haddad PM. Antidepressant discontinuation syndromes. Drug Saf 2001;24:183-197.
86. Desmond MM, Wilson GS. Neonatal abstinence syndrome: recognition and diagnosis. Addict Dis 1975;2:113-121.
87. Abdel-Latif ME, Pinner J, Clews S, et al. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics 2006;117:e1163-e1169.
88. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Med 2004;158:312-316.
89. Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006;63:898-906.
90. Dilsaver SC, Greden JF. Antidepressant withdrawal phenomena. Biol Psychiatry 1984;19:237-256.
91. Vlaminck JJ, van Vliet IM, Zitman FG. [Withdrawal symptoms of antidepressants.] Ned Tijdschr Geneeskd 2005;149:698-701.
92. MICROMEDEX® Healthcare Series [computer program]. Version 3. Greenwood Village, Colorado: MICROMEDEX, 2000.
93. Roofthooft DWE, Bloem BR, Brouwer OF, et al. Neonatale myoclonieën na maternaal clomipramine-gebruik tijdens de zwangerschap. Tijdschr Kindergeneeskd 2001;69:120-125.
94. Altshuler LL, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996;153:592-606.
95. Reprorisk system® [computer program]. Greenwood Village, Colorado: Thompsom Micromedex, 2004.
96. Reprotext system® [computer program]. Greenwood Village, Colorado: Thompsom Micromedex, 2004.
97. Withdrawing patients from antidepressants. Drug Ther Bull 1999;37:49-52.
98. Diamond BI, Borison RL, Katz R, et al. Rebound withdrawal reactions due to clomipramine. Psychopharmacol Bull 1989;25:209-212.
99. Garner EM, Kelly MW, Thompson DF. Tricyclic antidepressant withdrawal syndrome. Ann Pharmacother 1993;27:1068-1072.
100. Dilsaver SC, Kronfol Z, Sackellares JC, et al. Antidepressant withdrawal syndromes: evidence supporting the cholinergic overdrive hypothesis. J Clin Psychopharmacol 1983;3:157-164.
101. Charney DS, Heninger GR, Sternberg DE, et al. Abrupt discontinuation of tricyclic antidepressant drugs: evidence for noradrenergic hyperactivity. Br J Psychiatry 1982;141:377-386.
102. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005;293:2372-2383.
103. Gracious BL, Wisner KL. Phenelzine use throughout pregnancy and the puerperium: case report, review of the literature, and management recommendations. Depress Anxiety 1997;6:124-128.
104. Webster PA. Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet 1973;2:318-319.
105. Goldfarb C, Keating G. Use of antidepressants from conception to delivery. J Med Soc N J 1981;78:357-360.
106. Loughhead AM, Stowe ZN, Newport DJ, et al. Placental passage of tricyclic antidepressants. Biol Psychiatry 2005;59:287-290.
107. Shearer WT, Schreiner RL, Marshall RE. Urinary retention in a neonate secondary to maternal ingestion of nortriptyline. J Pediatr 1972;81:570-572.
108. Koren G. Discontinuation syndrome following late pregnancy exposure to antidepressants. Arch Pediatr Adolesc Med 2004;158:307-308.
109. Anderson GM, Czarkowski K, Ravski N, et al. Platelet serotonin in newborns and infants: ontogeny, heritability, and effect of in utero exposure to selective serotonin reuptake inhibitors. Pediatr Res 2004;56:418-422.
110. Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004;113:368-375.
111. Schatzberg AF, Haddad P, Kaplan EM, et al. Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. Discontinuation Consensus Panel. J Clin Psychiatry 1997;58(suppl 7):23-27.
112. Laine K, Heikkinen T, Ekblad U, et al. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003;60:720-726.
113. Goldstein DJ. Effects of third trimester fluoxetine exposure on the newborn. J Clin Psychopharmacol 1995;15:417-420.
114. Isbister GK, Dawson A, Whyte IM, et al. Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome? Arch Dis Child Fetal Neonatal Ed 2001;85:F147-F148.
115. Sanz EJ, las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005;365:482-487.
116. Ruchkin V, Martin A. SSRIs and the developing brain. Lancet 2005;365:451-453.
117. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997;336:258-262.
118. Gentile S. SSRIs in pregnancy and lactation: emphasis on neurodevelopmental outcome. CNS Drugs 2005;19:623-633.
119. Oberlander TF, Grunau RE, Fitzgerald C, et al. Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure. Pediatrics 2005;115:411-425.
120. Mohan CG, Moore JJ. Fluoxetine toxicity in a preterm infant. J Perinatol 2000;20:445-446.
121. Jessel N, Stiskal JA. Neonatal encephalopathy after antidepressant exposure during pregnancy. Z Geburtshilfe Neonatol 2004;208:75-76.
122. Comment on Herbst F, Gortner L. Paroxetine withdrawal syndrome as differential diagnosis of acute neonatal encephalophathy? Z Geburtsh Neonatol 2003;207:232-234.
123. Bot P, Stappen van der J, Seminmekrot B. Neonatal effects of selective serotonin receptor inhibitors (SSRI) exposure during pregnancy. Arch Dis Child Fetal Neonatal Ed 2006;91:F153-F156.
124. Suri R, Altshuler L, Hendrick V, et al. The impact of depression and fluoxetine treatment on obstetrical outcome. Arch Womens Ment Health 2004;7:193-200.
125. Da Costa D, Dritsa M, Larouche J, et al. Psychosocial predictors of labor/delivery complications and infant birth weight: a prospective multivariate study. J Psychosom Obstet Gynaecol 2000;21:137-148.
126. Ohmi H, Hirooka K, Mochizuki Y. Fetal growth and the timing of exposure to maternal smoking. Pediatr Int 2002;44:55-59.
127. Visscher WA, Feder M, Burns AM, et al. The impact of smoking and other substance use by urban women on the birthweight of their infants. Subst Use Misuse 2003;38:1063-1093.
128. Haddad PM, Pal BR, Clarke P, et al. Neonatal symptoms following maternal paroxetine treatment: serotonin toxicity or paroxetine discontinuation syndrome? J Psychopharmacol 2005;19:554-557.
129. Morag I, Batash D, Keidar R, et al. Paroxetine use throughout pregnancy: does it pose any risk to the neonate? J Toxicol Clin Toxicol 2004;42:97-100.
130. Jaiswal S, Coombs RC, Isbister GK. Paroxetine withdrawal in a neonate with historical and laboratory confirmation. Eur J Pediatr 2003;162:723-724.
131. Duijvestijn YC, Kalmeijer MD, Passier AL, et al. Neonatal intraventricular haemorrhage associated with maternal use of paroxetine. Br J Clin Pharmacol 2003;56:581-582.
132. Heikkinen T, Ekblad U, Kero P, et al. Citalopram in pregnancy and lactation. Clin Pharmacol Ther 2002;72:184-191.
133. Sivojelezova A, Shuhaiber S, Sarkissian L, et al. Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am J Obstet Gynecol 2005;193:2004-2009.
134. Chun-Fai-Chan B, Koren G, Fayez I, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 2005;192:932-936.
135. Szabadi E. Fluvoxamine withdrawal syndrome. Br J Psychiatry 1992;160:283-284.
136. de Moor RA, Mourad L, ter HJ, et al. [Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy.] Ned Tijdschr Geneeskd 2003;147:1370-1372.
137. Wyeth pharmaceuticals. Use of venlafaxine in pregnancy. Data on File. Wyeth Pharmaceuticals, Madison, NJ, 2006.
138. Kesim M, Yaris F, Kadioglu M, et al. Mirtazapine use in two pregnant women: is it safe? Teratology 2002;66:204.
139. Santos RP, Pergolizzi JJ. Transient neonatal jitteriness due to maternal use of sertraline (Zoloft). J Perinatol 2004;24:392-394.
140. Oca MJ, Donn SM. Association of maternal sertraline (Zoloft) therapy and transient neonatal nystagmus. J Perinatol 1999;19:460-461.
141. Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn. Committee on Drugs. American Academy of Pediatrics. Pediatrics 2000;105:880-887.
142. Finnegan LP, Connaughton JF Jr, Kron RE, et al. Neonatal abstinence syndrome: assessment and management. Addict Dis 1975;2:141-158.
143. Boukydis CF, Bigsby R, Lester BM. Clinical use of the Neonatal Intensive Care Unit Network Neurobehavioral Scale. Pediatrics 2004;113:679-689.
144. Lester BM, Tronick EZ. History and description of the Neonatal Intensive Care Unit Network Neurobehavioral Scale. Pediatrics 2004;113:634-640.
145. Lester BM, Tronick EZ, LaGasse L, et al. Summary statistics of neonatal intensive care unit network neurobehavioral scale scores from the maternal lifestyle study: a quasinormative sample. Pediatrics 2004;113:668-675.
146. Zahorodny W, Rom C, Whitney W, et al. The neonatal withdrawal inventory: a simplified score of newborn withdrawal. J Dev Behav Pediatr 1998;19:89-93.
147. Streiner DL, Norman GR. Health Measurement Scales: A Practical Guide to Their Development and Use. 3rd ed. New York: Oxford University Press, 2003.
148. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-713.
149. Kent LS, Laidlaw JD. Suspected congenital sertraline dependence. Br J Psychiatry 1995;167:412-413.
150. Bloem BR, Lammers GJ, Roofthooft DW, et al. Clomipramine withdrawal in newborns. Arch Dis Child Fetal Neonatal Ed 1999;81:F77.
151. Nijhuis IJ, Kok-Van Rooij GW, Bosschaart AN. Withdrawal reactions of a premature neonate after maternal use of paroxetine. Arch Dis Child Fetal Neonatal Ed 2001;84:F77.
152. Nordeng H, Spigset O. Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy: effects on the infant. Drug Saf 2005;28:565-581.
153. Spencer MJ. Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics 1993;92:721-722.
154. Hendrick V, Smith LM, Suri R, et al. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 2003;188:812-815.
155. Nordeng H, Lindemann R, Perminov KV, et al. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 2001;90:288-291.
156. Herbst F, Gortner L. [Paroxetine withdrawal syndrome as differential diagnosis of acute neonatal encephalopathy.] Z Geburtshilfe Neonatol 2003;207:232-234.
157. Stiskal JA, Kulin N, Koren G, et al. Neonatal paroxetine withdrawal syndrome. Arch Dis Child Fetal Neonatal Ed 2001;84:F134-F135.
158. Cowe L, Lloyd DJ, Dawling S. Neonatal convulsions caused by withdrawal from maternal clomipramine. Br Med J (Clin Res Ed) 1982;284:1837-1838.
159. Boringa JB, de Jong GM, Touw DJ. [Neonatal withdrawal symptoms following the use of clomipramine during pregnancy.] Ned Tijdschr Geneeskd 1992;136:1473-1475.
160. Garbis-Berkvens JM, Stricker BH, van der Zijden WA. [Neurological symptoms in newborn infants due to the administration of psychopharmacologic agents during pregnancy.] Ned Tijdschr Geneeskd 1993;137:1885-1887.
161. Cohen LS, Heller VL, Bailey JW, et al. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 2000;48:996-1000.
162. Laine K, Kytola J, Bertilsson L. Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy. Ther Drug Monit 2004;26:685-687.
163. Ostergaard GZ, Pedersen SE. Neonatal effects of maternal clomipramine treatment. Pediatrics 1982;69:233-234.
164. Schimmell MS, Katz EZ, Shaag Y, et al. Toxic neonatal effects following maternal clomipramine therapy. J Toxicol Clin Toxicol 1991;29:479-484.
165. Mhanna MJ, Bennet JB, Izatt SD. Potential fluoxetine chloride (Prozac) toxicity in a newborn. Pediatrics 1997;100:158-159.
166. Dahl ML, Olhager E, Ahlner J. Paroxetine withdrawal syndrome in a neonate. Br J Psychiatry 1997;171:391-392.
167. Musa AB, Smith CS. Neonatal effects of maternal clomipramine therapy. Arch Dis Child 1979;54:405.
168. Balant-Gorgia AE, Gex-Fabry M, Balant LP. Clinical pharmacokinetics of clomipramine. Clin Pharmacokinet 1991;20:447-462.
169. Costei AM, Kozer E, Ho T, et al. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002;156:1129-1132.
170. Abebe-Campino G, Offer D, Stahl B, et al. Cardiac arrhythmia in a newborn infant associated with fluoxetine use during pregnancy. Ann Pharmacother 2002;36:533-534.
171. Dubnov G, Fogelman R, Merlob P. Prolonged QT interval in an infant of a fluoxetine treated mother. Arch Dis Child 2005;90:972-973.